Use of Ursodeoxycholic Acid and the Risk of Severe Coronavirus Disease 2019 in Elderly Patients with Viral Hepatitis

• Published in: Internal Medicine Vol. 64; no. 15; pp. 4856-24 - 2306
• Main Authors: Okushin, Kazuya, Ikeuchi, Kazuhiko, Saito, Makoto, Kishida, Toshiyuki, Kado, Akira, Fujishiro, Mitsuhiro, Moriya, Kyoji, Yotsuyanagi, Hiroshi, Koike, Kazuhiko, Tsutsumi, Takeya
• Format: Journal Article
• Language: English
• Published: Japan The Japanese Society of Internal Medicine 2025; Japan Science and Technology Agency
• Subjects: Aged; Aged, 80 and over; chemoprevention; Cirrhosis; Coronaviruses; COVID-19; COVID-19 - epidemiology; COVID-19 - mortality; COVID-19 Drug Treatment; Diabetes mellitus (non-insulin dependent); Female; Hepatitis; Hepatitis B; Hepatitis B, Chronic - complications; Hepatitis B, Chronic - drug therapy; Hepatitis C, Chronic - complications; Hepatitis C, Chronic - drug therapy; Hepatocellular carcinoma; Hospital Mortality; Humans; Male; Middle Aged; Mortality; novel coronavirus disease 2019; Original; Patients; Propensity Score; Retrospective Studies; SARS-CoV-2; Severe acute respiratory syndrome; severe acute respiratory syndrome coronavirus; Severity of Illness Index; Subclinical infection; Ursodeoxycholic acid; Ursodeoxycholic Acid - adverse effects; Ursodeoxycholic Acid - therapeutic use; severe acute respiratory syndrome coronavirus; chemoprevention; ursodeoxycholic acid; novel coronavirus disease 2019

Objective Although the management of coronavirus disease 2019 (COVID-19) has improved, chemoprevention remains a challenge. We recently identified that ursodeoxycholic acid (UDCA) is associated with subclinical infection with severe acute respiratory syndrome coronavirus, implying a reduction in the...